Drug intelligence / Profile preview

DC-TB-118

Development stage: Preclinical
Lead developer: Gilead Sciences
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

DC-TB-118 is a preclinical-stage antibody-drug conjugate (ADC) being developed by Tubulis for the treatment of solid tumors. As part of Tubulis' proprietary pipeline, DC-TB-118 is engineered using advanced conjugation technologies designed to enhance the stability and therapeutic index of the conjugate. The specific biological target and the nature of the cytotoxic payload are currently undisclosed. The program aims to provide a targeted therapeutic option for patients with various solid malignancies by delivering potent anti-cancer agents directly to tumor cells while minimizing systemic toxicity.

Targets

TOP1 (DNA Topoisomerase I)

Beyond the preview

Go deeper on DC-TB-118.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DC-TB-118.

Explore the full profile